Biovail Seeks To Block Generic Competiton For Wellbutrin XL
Watson informed Biovail in a letter dated July 21, 2005 that it had filed an Abbreviated New Drug Application with the Food and Drug Administration in hopes of producing a generic version of Wellbutrin XL.
Biovail asked Watson to provide information about the drug that would allow the company to determine whether or not its patent had...
Already a subscriber? Click here to login